Literature DB >> 24332767

Ten common mistakes in the management of lupus nephritis.

Bhadran Bose1, Earl D Silverman2, Joanne M Bargman3.   

Abstract

Management of patients with lupus nephritis can be complex and challenging. We suggest that there are some widely held misconceptions about lupus, and unfortunately, these underpin the treatment of many patients. There is little evidence to support the common assumption that intravenous pulse cyclophosphamide is the best treatment for lupus nephritis. Although there is much focus on which immunosuppressive agent to use, too little attention is paid to the proper dose and duration of corticosteroids and concomitant therapy with antimalarial agents. Many clinicians reflexively perform kidney biopsies when these biopsies may be high risk and not influence therapy. There is little emphasis on or awareness of nonadherence to therapy, which is an underappreciated cause of treatment resistance. Resolution of proteinuria and hematuria can take a long time, and immunotherapy should not be intensified based on urine sediment alone. Furthermore, the intensity of the immunosuppression must be considered in the context of lupus nephritis class and duration of kidney damage. Finally, clinicians are aware of the risks of pregnancy in the face of active lupus, but assume that their patients also are aware of this and forget to discuss this with them. With a combined experience of more than 50 years in managing children and adults with lupus, we offer our impression of recurrent mistakes in the management of lupus in general, with a focus on treatment of lupus nephritis.
Copyright © 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antimalarial agents and nonadherence; azathioprine; cyclophosphamide; lupus nephritis

Mesh:

Substances:

Year:  2013        PMID: 24332767     DOI: 10.1053/j.ajkd.2013.10.056

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  8 in total

1.  [Lupus nephritis].

Authors:  S Melderis; T Wiech; C Iking-Konert; O M Steinmetz
Journal:  Z Rheumatol       Date:  2018-09       Impact factor: 1.372

2.  Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort.

Authors:  Jayne Little; Ben Parker; Mark Lunt; John G Hanly; Murray B Urowitz; Ann E Clarke; Juanita Romero-Diaz; Caroline Gordon; Sang-Cheol Bae; Sasha Bernatsky; Daniel J Wallace; Joan T Merrill; Jill Buyon; David A Isenberg; Anisur Rahman; Ellen M Ginzler; Michelle Petri; Mary Anne Dooley; Paul Fortin; Dafna D Gladman; Kristjan Steinsson; Rosalind Ramsey-Goldman; Munther A Khamashta; Cynthia Aranow; Meggan Mackay; Graciela S Alarcón; Susan Manzi; Ola Nived; Andreas Jönsen; Asad A Zoma; Ronald F van Vollenhoven; Manuel Ramos-Casals; Guillermo Ruiz-Irastorza; Sung Sam Lim; Kenneth C Kalunian; Murat Inanc; Diane L Kamen; Christine A Peschken; Soren Jacobsen; Anca Askanase; Jorge Sanchez-Guerrero; Ian N Bruce
Journal:  Rheumatology (Oxford)       Date:  2018-04-01       Impact factor: 7.580

3.  Renal Remission Status and Longterm Renal Survival in Patients with Lupus Nephritis: A Retrospective Cohort Analysis.

Authors:  Julie E Davidson; Qinggong Fu; Beulah Ji; Sapna Rao; David Roth; Laurence S Magder; Michelle Petri
Journal:  J Rheumatol       Date:  2018-03-01       Impact factor: 4.666

4.  Clinical characteristics of children with membranous lupus nephritis: the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry.

Authors:  A Boneparth; S E Wenderfer; L Nandini Moorthy; S M Radhakrishna; A C P Sagcal-Gironella; E von Scheven
Journal:  Lupus       Date:  2016-08-20       Impact factor: 2.911

5.  Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis.

Authors:  Farah Tamirou; David D'Cruz; Shirish Sangle; Philippe Remy; Carlos Vasconcelos; Christoph Fiehn; Maria del Mar Ayala Guttierez; Inge-Magrethe Gilboe; Maria Tektonidou; Daniel Blockmans; Isabelle Ravelingien; Véronique le Guern; Geneviève Depresseux; Loïc Guillevin; Ricard Cervera; Frédéric A Houssiau
Journal:  Ann Rheum Dis       Date:  2015-03-10       Impact factor: 19.103

6.  Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital.

Authors:  Yohei Hosokawa; Hiroshi Oiwa
Journal:  Intern Med       Date:  2020-07-07       Impact factor: 1.271

7.  Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort.

Authors:  Selin Cooper Blenkinsopp; Qinggong Fu; Yulia Green; Anuradha Madan; Patricia Juliao; Daniel W Goldman; David A Roth; Michelle A Petri
Journal:  Lupus Sci Med       Date:  2022-08

8.  Haematuria on the Spanish Registry of Glomerulonephritis.

Authors:  Claudia Yuste; Francisco Rivera; Juan Antonio Moreno; Juan Manuel López-Gómez
Journal:  Sci Rep       Date:  2016-01-28       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.